summit clinical trial tirzepatide In the trial, researchers examined cardiovascular outcomes of treatment with in patients with heart failure with preserved ejection fraction and obesity. Full results and Plain Language Summary: https://nej.md/4hRGaTY Medthreads New in the January 30,

Furthermore, the GLP-1 secretion, which was inhibited by pasireotide in response to a high glucose level with L-glutamine and sodium butyrate stimulation, was significantly lower than the basal GLP-1 secretion in the low-glucose (0.1 mM) state in GLUTag cells (Fig

Guidelines call for restricting Wegovy to either obese people or those overweight with a body mass index of at least 27 and one or more weight-related issues, like high blood pressure or Type 2 diabetes

Built to keep you informed, grounded in the evidence, and prepared for whats next

Researchers building long-term protocols should note that 4mg may become the standard entry-level prescribed dose once approval occurs, making current data at this level especially relevant for understanding what the future standard of care might look like